Demand for non-clinical development support drives L2D expansion
This article was originally published in Scrip
An increase in demand from small- and medium-sized drug development companies for non-clinical development support has led to one young CRO, Leads to Development (L2D), opening new two new offices alongside its Paris, France base.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.